Identification of Clinical and Pharmacogenetic Factors Influencing Metformin Response in Type 2 Diabetes Mellitus
Noelia Pérez-Gómez, María Dolores Fernández-Ortega, Miren Elizari-Roncal, Estefanía Santos-Mazo, Laura de la Maza-Pereg, Sara Calvo, Raquel Alcaraz, Antonio Sanz-Solas, Raquel Vinuesa Campo, Miriam Saiz‐Rodríguez
Abstract
Metformin, a hypoglycemic drug for Type 2 diabetes mellitus, shows variability in pharmacokinetics and response due to membrane transporters. This study followed 34 Type 2 diabetes mellitus patients on metformin treatment. Genetic variants in 11 metformin transport-related genes were analyzed, revealing associations. Specifically, SLC47A1 rs2289669 A/A and SLC22A4 rs1050152 T/T genotypes correlated with glycated hemoglobin values at 6 months. SLC47A1 rs2289669 G/A genotype influenced glucose levels at 6 months, while SLC29A4 rs3889348 A/A, SLC47A1 rs2289669 A/A, SLC22A4 rs1050152 C/T and SLC47A2 rs12943590 A/A genotypes were linked to glucose levels at 12 months. Additionally, ABCB1 rs2032582 C/A and ABCG2 rs2231137 C/T genotypes impacted cholesterol levels at 12 months. These findings shed light on metformin response determinants, offering insights for further research.